Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.32 |
| ▸ | PIM1 | P11309 | 2/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24171001 | 1.00 | HRH3 (0.34) | HRH3HDAC1HDAC8HDAC6SLC6A2 | |
| SCHEMBL24171113 | 1.00 | HRH3 (0.34) | HRH3HDAC1HDAC8HDAC6SLC6A2 | |
| SCHEMBL24171579 | 0.90 | HRH3 (0.33) | HRH3HDAC1HDAC8HDAC6SLC6A2 | |
| SCHEMBL24171580 | 0.90 | HRH3 (0.33) | HRH3HDAC1HDAC8HDAC6SLC6A2 | |
| SCHEMBL24171012 | 0.90 | HRH3 (0.33) | HRH3HDAC1HDAC8HDAC6SLC6A2 | |
| SCHEMBL24171103 | 0.83 | HDAC1 (0.39) | HRH3HDAC1HDAC8HDAC6SLC6A2 | |
| SCHEMBL12257331 | 0.83 | HDAC1 (0.39) | HRH3HDAC1HDAC8HDAC6SLC6A2 | |
| SCHEMBL24171110 | 0.83 | HDAC1 (0.39) | HRH3HDAC1HDAC8HDAC6SLC6A2 | |
| SCHEMBL23710160 | 0.81 | HRH3 (0.36) | HRH3HDAC1HDAC8HDAC6SLC6A2 | |
| SCHEMBL23710143 | 0.81 | HRH3 (0.36) | HRH3HDAC1HDAC8HDAC6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002290-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3858832-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002290-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | BCL2L11, BCL2, BCL2L2 | HRH3 4374/4885HDAC1 468/4885HDAC8 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.